St John's DermAcademy Podcast

Episode 17: Part 2 - Eczema Therapeutics

In this episode our host Dr Sarah Drummond speaks with Professor Catherine Smith and Dr Andrew Pink about eczema therapeutics:• The use of JAK inhibitors licensed for use in managing eczema including their mechanism of action, monitoring requirements and potential side effects. • Newer agents currently under investigation. • The BEACON trial Recorded: 19 March 2024For more information, visit: www.stjohnsdermacademy.com/podcasts Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical needs they may have.

Episode 16: Part 1 - Eczema Therapeutics

In this episode our host Dr Sarah Drummond speaks with Professor Catherine Smith and Dr Andrew Pink about eczema therapeutics:• Where conventional systemic agents fit within the evolving landscape of eczema therapeutics.• The biologic agents licensed for use in eczema including their mechanism of action, monitoring requirements and potential side effects.Recorded: 19 March 2024For more information, visit: www.stjohnsdermacademy.com/podcasts Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical needs they may have.

Episode 15: Part 2: Immunobullous disorders - Pemphigus vulgaris

In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about pemphigus vulgaris: • The clinical features of pemphigus vulgaris and other variants of pemphigus.  • The step-wise management of pemphigus vulgaris including an approach to managing severe disease and the use of rituximab and intravenous immunoglobulin . Resources and further reading: • British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris, 2017 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.15930) • European guidelines for the management of pemphigus vulgaris and foliaceous initiated by the European Academy of Dermatology and Venereology, 2020 (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16752) • Rituximab and Covid-19 Risk – a single-centre cohort study (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00004-8/fulltext) • Phase 2 Study of efficacy and safety of Rilzabrutinib for patients with pemphigus vulgaris (https://pubmed.ncbi.nlm.nih.gov/35686647/) • Phase 2 Study of the use of Efgartigimod for patients with pemphigus vulgaris and foliaceous (https://pubmed.ncbi.nlm.nih.gov/34608631/) Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.Recorded date: 26 January 2024

Episode 14: Part 1: Immunobullous disorder - Bullous pemphigoid

In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about bullous pemphigoid:• The clinical features and risk factors for developing bullous pemphigoid  • How to differentiate bullous pemphigoid from other subepidermal blistering disorders  • Management of bullous pemphigoid including:  o Preferred first and second line agents  o How and when to reduce treatment  o What to do in severe and refractory cases   Resources and further reading: • European guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology, 2022 (updated) (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18220) • British Association of Dermatologists’ guidelines for the management of bullous pemphigoid, 2012 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.12072)Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series. Recorded date: 26 January 2024Please visit our website https://www.stjohnsdermacademy.com/podcasts for episode notes and references. 

Episode 13: Vulval skin conditions - Part 2: Management

In this episode our host Dr Justin Bui speaks to Dr Fiona Lewis about vulval skin conditions.In this episode we discuss…·       Management of lichen sclerosus, including what to do when topical steroids are not effective·       Management of vulval eczema and psoriasis ·       When to refer to a tertiary service  Please visit our website https://www.stjohnsdermacademy.com/podcasts for episode notes and references.